（文章来源：证券日报） 证券日报网讯 8月28日晚间，步长制药发布公告称，公司全资子公司陕西步长高新制药有限公司近日收 到国家药品监督管理局核准签发的关于磷酸奥司他韦胶囊的《药品注册证书》。 ...

Core Insights - Step Long Pharmaceutical celebrates its 32nd anniversary, emphasizing its commitment to clinical needs, theoretical breakthroughs, and digital technology integration [1][2] - The company has developed key cardiovascular products based on the "Brain-Heart Treatment" theory, which has been validated through extensive clinical and experimental research [1] - Step Long Pharmaceutical has introduced a comprehensive health product range for women, expanding its clinical solutions [1] Research and Development - The company integrates artificial intelligence and big data into its drug development and production processes, enhancing drug quality and industry efficiency [1] - A new model of "Traditional Chinese Medicine + AI" has been established, leading to the development of a Chinese medicine combination warning system that has provided over ten thousand safety alerts [1] Production and Quality Control - Step Long Pharmaceutical has achieved full-chain digital control from herbal planting to drug production, with advanced quality control systems in place [2] - The production line for Brain-Heart Capsules features a comprehensive quality control traceability system, while the packaging line for Stable Heart Granules has reached a high level of automation [2] Agricultural Collaboration - The company has built a digital platform for herbal planting with 350 nodes, ensuring quality control and collaborating with over 5,000 farmers, resulting in an average income increase of over 30% for farmers [2] Future Directions - Step Long Pharmaceutical aims to continue focusing on "modern traditional Chinese medicine, technological traditional Chinese medicine, and quality traditional Chinese medicine," promoting the integration of traditional Chinese medicine with high technology [2]

Core Viewpoint - The company, Buchang Pharma, is undergoing a significant transformation from a traditional Chinese medicine enterprise to an innovative pharmaceutical group, showcasing strong financial performance and strategic advancements in the first half of 2025 [1] Group 1: Financial Performance - In the first half of 2025, Buchang Pharma reported a revenue of 5.664 billion yuan and a net profit attributable to shareholders of 628 million yuan, with a net cash inflow from operating activities of 959 million yuan [1] - The company plans to distribute a cash dividend of 3.9 yuan per share, amounting to a total of 411 million yuan, which represents 65.52% of its net profit [6] Group 2: R&D and Product Development - Buchang Pharma's subsidiary received approval for the registration of "Adalimumab Injection," targeting eight autoimmune diseases, indicating a strategic focus on high-demand therapeutic areas [2] - The company has a diverse R&D pipeline, with multiple products such as a quadrivalent influenza vaccine and a varicella vaccine making significant progress [2][3] - The company is building a multi-faceted R&D structure that integrates traditional Chinese medicine, biological drugs, and chemical drugs, enhancing its competitive edge [3] Group 3: Strategic Initiatives - The company is actively pursuing internationalization, having signed an exclusive supply agreement with a Philippine pharmaceutical company, which supports the expansion of traditional Chinese medicine into Southeast Asia [4] - Buchang Pharma has made significant strides in smart manufacturing, achieving full-process digital management in its production, which has improved efficiency and product quality [4] Group 4: Corporate Social Responsibility - Since its establishment, Buchang Pharma has contributed over 32 billion yuan in taxes, supporting local economic development and demonstrating its commitment to social responsibility [6] - The company has sponsored the "Together, Building a Chinese Heart" public welfare initiative for 18 consecutive years, benefiting over 1 million people [7] Group 5: Future Outlook - Looking ahead, Buchang Pharma aims to deepen its innovation-driven development strategy while expanding its presence in chemical and biological drug sectors, positioning itself for greater market and capital gains [7]

2025年8月28日，步长制药(603858.SH)发布2025年中报。 公司营业总收入为56.64亿元，在已披露的同业公司中排名第3，较去年同报告期营业总收入增加2.32亿元，同比较去年同期上涨4.27%。归母净利润为6.28亿 元，在已披露的同业公司中排名第8，较去年同报告期归母净利润增加3.96亿元，同比较去年同期上涨171.24%。经营活动现金净流入为9.59亿元，在已披露 的同业公司中排名第4，较去年同报告期经营活动现金净流入增加4.62亿元，实现2年连续上涨，同比较去年同期上涨92.87%。 公司最新资产负债率为48.53%，较上季度资产负债率减少0.80个百分点。 公司最新毛利率为62.38%，在已披露的同业公司中排名第22，较上季度毛利率增加0.58个百分点，实现4个季度连续上涨，较去年同期毛利率增加5.37个百 分点。最新ROE为5.84%，在已披露的同业公司中排名第15，较去年同期ROE增加3.79个百分点。 公司摊薄每股收益为0.59元，在已披露的同业公司中排名第10，较去年同报告期摊薄每股收益增加0.38元，同比较去年同期上涨181.23%。 公司最新总资产周转率为0.29次，在已披露 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月28日，步长制药发布公告称，公司全资子公司陕西步 长高新制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦胶囊的《药品注册证 书》。公告显示，该药品用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗，以及成人和13岁及13岁 以上青少年的甲型和乙型流感的预防。 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-161 关于全资子公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）近日获悉全资子公司杨凌 步长制药有限公司（以下简称"杨凌步长"）获得陕西省药品监督管理局许可， 同意杨凌步长《药品生产许可证》药品受托委托有效期的变更，其他内容不变。 公司全资子公司山东丹红制药有限公司（以下简称"山东丹红"）获得山东省药 品监督管理局许可，同意山东丹红《药品生产许可证》药品委托情况的变更，其 他内容不变。 法定代表人：王益民 山东步长制药股份有限公司 现将相关情况公告如下： 一、杨凌步长 （一）药品生产许可证相关情况 企业名称：杨凌步长制药有限公司 注册地址：陕西省杨凌示范区新桥南路 许可证编号：陕 20200003 分类码：AhzBhChz 企业负责人：张伟 质量负责人：冯煜 生产地址和生产范围：陕西省杨凌示范区新桥南路；片剂（含抗肿瘤类、激 1 素类），硬胶囊剂（含抗肿瘤类），颗粒剂，合剂，糖浆剂（含中药 ...

山东步长制药股份有限公司（以下简称"公司"）全资子公司陕西步长高新 制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦胶囊 的《药品注册证书》。现将有关信息披露如下： | 药品名称 | 磷酸奥司他韦胶囊 | | --- | --- | | 主要成份 | 磷酸奥司他韦 | | 剂型 | 胶囊剂 | | 规格 | 75mg（按 C₁₆H₂₈N₂O₄计） | | 申请事项 | 药品注册(境内生产) | | 注册分类 | 化学药品 4 类 | | 处方药/非处方药 | 处方药 | | 上市许可持有人 | 名称：陕西步长高新制药有限公司 地址：陕西省西安市高新区新型工业园西部大道 70 号 | | | 名称：陕西步长高新制药有限公司 | | 生产企业 | 地址：陕西省西安市高新区新型工业园西部大道 70 号 | | 药品批准文号 | 国药准字 H20255129 | | 药品批准文号有效期 | 至 2030 年 08 月 18 日 | | 证书编号 | 2025S02494 | | | 根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证 | | 审批 ...

Core Viewpoint - The approval of the drug registration certificate for Oseltamivir Phosphate Capsules by the National Medical Products Administration is a significant milestone for the company, enhancing its product portfolio and production capacity, which is expected to positively impact future operations [1] Group 1 - The company announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules [1] - Oseltamivir Phosphate Capsules are primarily used for the treatment of influenza A and B in adults and children aged one year and older, as well as for prevention in adults and adolescents aged 13 years and older [1] - The registration of this drug is beneficial for the company to optimize its product structure and maintain stable production capacity to meet market demand [1]

步长制药公告，全资子公司陕西步长高新制药有限公司近日收到国家药品监督管理局核准签发的磷酸奥 司他韦胶囊《药品注册证书》。该药品主要用于成人和1岁及以上儿童的甲型和乙型流感治疗，以及成 人和13岁及以上青少年的甲型和乙型流感预防。2022年至2024年中国城市实体药店年度销售额分别为 1.52亿元、8.24亿元和7.76亿元。截至公告披露日，公司在该项目上已投入研发费用约1296.12万元。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on August 28, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Buchang Pharmaceutical (603858) with a closing price of 20.02, up 5.59% and a trading volume of 325,000 shares, totaling 654 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 20.40, up 5.37% with a trading volume of 159,300 shares, totaling 324 million yuan [1] - Jilin Aodong (000623) closed at 20.34, up 1.75% with a trading volume of 239,000 shares, totaling 479 million yuan [1] - Conversely, significant decliners included: - Xinda Pharmaceutical (002873) with a closing price of 12.00, down 4.76% and a trading volume of 304,000 shares, totaling 364 million yuan [2] - Qidi Pharmaceutical (000590) closed at 12.22, down 4.61% with a trading volume of 221,600 shares, totaling 274 million yuan [2] - Kangjia Pharmaceutical (600557) closed at 17.22, down 4.39% with a trading volume of 313,700 shares, totaling 537 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors contributed a net inflow of 930 million yuan [2] - Key stocks with significant capital flow included: - Zhendong Pharmaceutical (300158) with a net inflow of 67.58 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 13.62 million yuan from institutional investors [3] - Tianmu Pharmaceutical (600671) with a net inflow of 7.33 million yuan from institutional investors [3]